{"id":"lapatinib-capecitabine","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Diarrhea"},{"rate":"15-30","effect":"Hand-foot skin reaction"},{"rate":"25-40","effect":"Nausea"},{"rate":"20-35","effect":"Fatigue"},{"rate":"15-25","effect":"Vomiting"},{"rate":"15-25","effect":"Decreased appetite"},{"rate":"10-20","effect":"Rash"},{"rate":"5-10","effect":"Cardiac dysfunction (lapatinib)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lapatinib is a dual tyrosine kinase inhibitor that blocks HER2 and EGFR signaling, preventing tumor cell proliferation and survival in HER2-overexpressing cancers. Capecitabine is a fluoropyrimidine prodrug that is metabolized to 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis. The combination provides complementary cytostatic and cytotoxic effects against HER2-positive malignancies.","oneSentence":"Lapatinib inhibits HER2 and EGFR tyrosine kinases while capecitabine is a prodrug that converts to 5-fluorouracil to inhibit thymidylate synthase, together targeting HER2-positive breast cancer through dual mechanisms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:16.024Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive metastatic breast cancer"},{"name":"HER2-positive early-stage breast cancer (adjuvant/neoadjuvant setting)"}]},"trialDetails":[{"nctId":"NCT03523585","phase":"PHASE3","title":"DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2018-08-01","conditions":"Breast Cancer","enrollment":608},{"nctId":"NCT01494662","phase":"PHASE2","title":"HKI-272 for HER2-Positive Breast Cancer and Brain Metastases","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2012-02","conditions":"Breast Cancer","enrollment":140},{"nctId":"NCT00680901","phase":"PHASE3","title":"LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-06-04","conditions":"Neoplasms, Gastrointestinal Tract","enrollment":545},{"nctId":"NCT06313983","phase":"PHASE3","title":"A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer","status":"RECRUITING","sponsor":"Tianjin Hemay Pharmaceutical Co., Ltd","startDate":"2022-01-08","conditions":"Breast Cancer","enrollment":339},{"nctId":"NCT00881621","phase":"PHASE2","title":"Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2009-08","conditions":"Pancreas Cancer","enrollment":17},{"nctId":"NCT01619111","phase":"PHASE3","title":"DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs","status":"COMPLETED","sponsor":"Prof. Wolfgang Janni","startDate":"2012-02","conditions":"HER2-negative Metastatic Breast Cancer, HER2-positive Circulating Tumor Cells","enrollment":105},{"nctId":"NCT03500380","phase":"PHASE2, PHASE3","title":"A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2018-04-24","conditions":"Breast Neoplasms, Breast Diseases, Capecitabine","enrollment":301},{"nctId":"NCT01300962","phase":"PHASE1","title":"Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2011-08","conditions":"Metastatic Breast Cancer","enrollment":47},{"nctId":"NCT03262935","phase":"PHASE3","title":"SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Byondis B.V.","startDate":"2017-12-15","conditions":"Metastatic Breast Cancer","enrollment":437},{"nctId":"NCT01873833","phase":"PHASE2","title":"Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2013-07-29","conditions":"HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer","enrollment":10},{"nctId":"NCT03084939","phase":"PHASE3","title":"Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-04-24","conditions":"Breast Cancer","enrollment":351},{"nctId":"NCT00807859","phase":"PHASE1","title":"Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-03-09","conditions":"Breast Cancer, Breast Neoplasms, Breast Tumors","enrollment":65},{"nctId":"NCT04850625","phase":"","title":"Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine","status":"COMPLETED","sponsor":"Fudan University","startDate":"2020-01-15","conditions":"Breast Cancer","enrollment":224},{"nctId":"NCT00508274","phase":"PHASE3","title":"Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-07-18","conditions":"Neoplasms, Breast","enrollment":52},{"nctId":"NCT01808573","phase":"PHASE3","title":"A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting","status":"COMPLETED","sponsor":"Puma Biotechnology, Inc.","startDate":"2013-03-29","conditions":"HER2+ Metastatic Breast Cancer (MBC)","enrollment":621},{"nctId":"NCT02650752","phase":"PHASE1","title":"Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-01-06","conditions":"Metastatic Breast Cancer, Central Nervous System (CNS) Metastases","enrollment":11},{"nctId":"NCT01471847","phase":"PHASE1","title":"A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-02","conditions":"Locally Advance Breast Cancer (LABC), Metastatic Breast Cancer (MBC)","enrollment":5},{"nctId":"NCT02362958","phase":"PHASE2","title":"A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-01-09","conditions":"HER2 Positive Breast Cancer","enrollment":159},{"nctId":"NCT03080805","phase":"PHASE3","title":"Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-05-03","conditions":"HER2 Positive Metastatic Breast Cancer","enrollment":240},{"nctId":"NCT00684983","phase":"PHASE2","title":"Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-30","conditions":"HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7","enrollment":64},{"nctId":"NCT01044433","phase":"PHASE2","title":"Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2009-10","conditions":"Head and Neck Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary","enrollment":44},{"nctId":"NCT00574171","phase":"PHASE2","title":"Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2007-09","conditions":"Metastatic Colorectal Cancer","enrollment":29},{"nctId":"NCT04185649","phase":"PHASE3","title":"The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Bio-Thera Solutions","startDate":"2018-07-01","conditions":"HER2-positive Advanced Breast Cancer","enrollment":410},{"nctId":"NCT01783756","phase":"PHASE1, PHASE2","title":"Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2013-06-26","conditions":"Central Nervous System Metastases, HER2-positive Breast Cancer, Male Breast Cancer","enrollment":9},{"nctId":"NCT02294786","phase":"PHASE2","title":"Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-12-17","conditions":"Cancer","enrollment":62},{"nctId":"NCT00820222","phase":"PHASE3","title":"Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-04-14","conditions":"Metastases, Brain","enrollment":540},{"nctId":"NCT00477464","phase":"PHASE2","title":"Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06","conditions":"Metastatic Breast Cancer, Neoplasms, Breast","enrollment":51},{"nctId":"NCT01357863","phase":"","title":"Role of Early Versus Late Switch to Lapatinib-Capecitabine","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2010-07-15","conditions":"Cancer","enrollment":3},{"nctId":"NCT00741260","phase":"PHASE1, PHASE2","title":"Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer","status":"COMPLETED","sponsor":"Puma Biotechnology, Inc.","startDate":"2008-12-09","conditions":"Breast Cancer","enrollment":105},{"nctId":"NCT00777101","phase":"PHASE2","title":"Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer","status":"COMPLETED","sponsor":"Puma Biotechnology, Inc.","startDate":"2009-02-04","conditions":"Advanced Breast Cancer, Breast Cancer","enrollment":233},{"nctId":"NCT02422199","phase":"PHASE1, PHASE2","title":"A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2015-05","conditions":"HER2 Positive Metastatic Breast Cancer","enrollment":128},{"nctId":"NCT01462604","phase":"","title":"Pilot Study of Patient's Adherence to TYKERB™/TYVERB™ + Capecitabine in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-23","conditions":"Cancer","enrollment":27},{"nctId":"NCT00790816","phase":"PHASE1","title":"Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-10","conditions":"Neoplasms, Breast","enrollment":500},{"nctId":"NCT02015169","phase":"PHASE2","title":"Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2012-07-09","conditions":"HER2-positive Gastric Cancer Patients With Liver Metastasis","enrollment":32},{"nctId":"NCT00536809","phase":"PHASE1","title":"Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-09-26","conditions":"Neoplasms, Colorectal","enrollment":12},{"nctId":"NCT02338245","phase":"PHASE2","title":"Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab","status":"COMPLETED","sponsor":"ASLAN Pharmaceuticals","startDate":"2014-12-29","conditions":"Metastatic Breast Cancer","enrollment":200},{"nctId":"NCT00721630","phase":"PHASE2","title":"Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-07","conditions":"Breast Cancer","enrollment":24},{"nctId":"NCT03085368","phase":"PHASE2, PHASE3","title":"A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2017-03-01","conditions":"HER2-positive Breast Cancer","enrollment":482},{"nctId":"NCT01847599","phase":"NA","title":"Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib","status":"TERMINATED","sponsor":"Centre Jean Perrin","startDate":"2011-09-06","conditions":"Metastatic Breast Cancer, Colorectal Cancer","enrollment":65},{"nctId":"NCT01013740","phase":"PHASE2","title":"Lapatinib in Combination With Vinorelbine","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-11-25","conditions":"Cancer","enrollment":112},{"nctId":"NCT00496366","phase":"PHASE2","title":"Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer","status":"TERMINATED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2007-07-23","conditions":"Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer","enrollment":11},{"nctId":"NCT00450203","phase":"PHASE2, PHASE3","title":"Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer","status":"UNKNOWN","sponsor":"Professor David Cunningham","startDate":"2007-10","conditions":"Oesophagogastric Cancer","enrollment":1103},{"nctId":"NCT00829166","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-02","conditions":"Breast Cancer","enrollment":991},{"nctId":"NCT01123473","phase":"PHASE2","title":"Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2010-12","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Gastric Cancer","enrollment":29},{"nctId":"NCT00338247","phase":"","title":"EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer","status":"APPROVED_FOR_MARKETING","sponsor":"Novartis","startDate":"2006-07","conditions":"Neoplasms, Breast","enrollment":""},{"nctId":"NCT01160094","phase":"","title":"Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-02","conditions":"Cancer","enrollment":288},{"nctId":"NCT00634088","phase":"PHASE1","title":"Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer","status":"TERMINATED","sponsor":"R-Pharm","startDate":"2008-06","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":13},{"nctId":"NCT00526669","phase":"PHASE2","title":"Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03","conditions":"Neoplasms, Gastrointestinal Tract","enrollment":68},{"nctId":"NCT01985893","phase":"PHASE2","title":"Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.","startDate":"2013-09","conditions":"Metastatic Breast Cancer","enrollment":""},{"nctId":"NCT01304784","phase":"PHASE1","title":"A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer","status":"COMPLETED","sponsor":"Merrimack Pharmaceuticals","startDate":"2011-01","conditions":"HER-2 Gene Amplification","enrollment":100},{"nctId":"NCT00437073","phase":"PHASE2","title":"Brain Metastases In ErbB2-Positive Breast Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2007-05","conditions":"Neoplasms, Breast","enrollment":22},{"nctId":"NCT01782651","phase":"","title":"Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08","conditions":"Neoplasms, Breast","enrollment":1},{"nctId":"NCT00632489","phase":"PHASE1","title":"LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2008-05","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT00962312","phase":"PHASE2","title":"Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2009-01","conditions":"Pancreatic Cancer","enrollment":9},{"nctId":"NCT01262469","phase":"PHASE2","title":"Evaluating Lapatinib + Capecitabine in Patients Aged 70 and Over With HER2 Metastatic Breast Cancer.","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2009-12","conditions":"Metastatic Breast Cancer, 70 Years Old Patients and Over, After One Line of Chemotherapy With Trastuzumab","enrollment":4},{"nctId":"NCT01238029","phase":"PHASE1","title":"Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Sponsor GmbH","startDate":"2010-10","conditions":"Metastatic Breast Cancer, HER2 Positive, First or Second Line Therapy","enrollment":12},{"nctId":"NCT01145404","phase":"PHASE2","title":"Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer","status":"TERMINATED","sponsor":"National Center for Tumor Diseases, Heidelberg","startDate":"2010-06","conditions":"GastroEsophageal Cancer","enrollment":76},{"nctId":"NCT00795678","phase":"","title":"Chemotherapeutic Agents in Brain/Breast","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2008-09","conditions":"Breast Cancer, Metastatic Cancer","enrollment":10},{"nctId":"NCT01050322","phase":"PHASE2","title":"Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment.","status":"COMPLETED","sponsor":"Latin American Cooperative Oncology Group","startDate":"2009-11","conditions":"BRMS1, Performance Status Zero to Two for Beginning the Study, Patient With a Maximum of One Chemotherapy","enrollment":142},{"nctId":"NCT00967031","phase":"PHASE2","title":"Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2009-04","conditions":"Breast Cancer, Metastatic Cancer","enrollment":45},{"nctId":"NCT00479856","phase":"PHASE2","title":"Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2007-11","conditions":"Relapsed Breast Cancer, Neoplasms, Breast","enrollment":9},{"nctId":"NCT00657137","phase":"PHASE2","title":"APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)","status":"TERMINATED","sponsor":"Tragara Pharmaceuticals, Inc.","startDate":"2008-04","conditions":"Breast Cancer","enrollment":12},{"nctId":"NCT00078572","phase":"PHASE3","title":"Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-03","conditions":"Breast Cancer","enrollment":408}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lapatinib+Capecitabine","genericName":"Lapatinib+Capecitabine","companyName":"Tianjin Hemay Pharmaceutical Co., Ltd","companyId":"tianjin-hemay-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lapatinib inhibits HER2 and EGFR tyrosine kinases while capecitabine is a prodrug that converts to 5-fluorouracil to inhibit thymidylate synthase, together targeting HER2-positive breast cancer through dual mechanisms. Used for HER2-positive metastatic breast cancer, HER2-positive early-stage breast cancer (adjuvant/neoadjuvant setting).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}